🇺🇸 FDA
Pipeline program

OT-101

OT-01-P201

Phase 3 small_molecule active

Quick answer

OT-101 for Pancreatic Ductal Adenocarcinoma is a Phase 3 program (small_molecule) at Oncotelic Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Oncotelic Therapeutics
Indication
Pancreatic Ductal Adenocarcinoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials